{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-058380","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.432450+00:00","generated_at":"2026-05-18T18:00:34.446849+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio to announce top line Phase 2 MINDFuL Alzheimer's data on June 30","bullets":["Conference call scheduled for June 30, 2025 at 8:00 AM ET to present top line Phase 2 MINDFuL results.","MINDFuL trial is a Phase 2 study in early Alzheimer's disease.","Press release issued June 26, 2025 announcing the upcoming data call.","Dial-in: +1-800-267-6316 (US) or +1-203-518-9783 (international), Conference ID: INMUNE.","Replay available through July 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-058380","json":"https://secwatch.observer/filing/0001213900-25-058380.json","markdown":"https://secwatch.observer/filing/0001213900-25-058380.md","text":"https://secwatch.observer/filing/0001213900-25-058380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025058380/0001213900-25-058380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025058380/ea0247096-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:00:34.446849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}